Search Results
Found 9 results
510(k) Data Aggregation
(196 days)
Kuros Biosciences B.V
MagnetOs MIS is intended to fill bony voids or gaps of the skeletal system, i.e., the extremities, pelvis, intervertebral disc space, and posterolateral spine. The osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. In the extremities, pelvis, intervertebral disc space and posterolateral spine, MagnetOs MIS may be used standalone or with autograft as a bone extender. When used in intervertebral body fusion procedures, MagnetOs MIS must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler.
MagnetOs MIS resorbs and is replaced with bone during the healing process.
MagnetOs MIS includes a synthetic, resorbable, osteoconductive bone void filler for the repair of bony defects. MagnetOs MIS graft material is a mixture of ceramic granules premixed with a synthetic polymeric binder that provides cohesion between the granules. The ceramic portion of MagnetOs MIS consists of 65–75% tri-calcium phosphate (TCP – Ca3(PO4)2) and 25–35% hydroxyapatite (HA – Ca10(PO4)6(OH)2) granules.
While the polymeric binder is rapidly resorbed after implantation, the granules of MagnetOs MIS guide the three-dimensional regeneration of bone in the defect site into which it is implanted. New bone will be deposited on the surface of the graft when placed next to viable host bone. The graft resorbs and is replaced by bone during the natural process of bone remodeling.
MagnetOs MIS graft material is provided in a 5cc pre-filled cartridge, packed together with a delivery system kit in a ready-to-use format. The MagnetOs MIS delivery system allows users to apply the bone graft into the defect. MagnetOs MIS is gamma-sterilized and sterile packaged for single use only.
Based on the provided FDA 510(k) clearance letter for MagnetOs MIS, the device is a bone void filler, which is a Class II medical device. The information details the device's characteristics and its substantial equivalence to predicate devices, primarily based on design, materials, and existing data from previously cleared products.
However, the provided document does not contain any information about acceptance criteria and a study that proves the device meets those criteria, specifically regarding AI/ML performance, diagnostic accuracy, or human reader improvement. The document focuses on the physical and material properties of the bone void filler and its delivery system, along with regulatory compliance related to device classification and manufacturing.
Therefore, I cannot fulfill your request to describe the acceptance criteria and the study proving the device meets them in the context of AI/ML performance, ground truth, expert adjudication, or MRMC studies. The document explicitly states: "No additional animal performance or clinical data was provided to support substantial equivalence for the proposed indications. Instead, animal and clinical data from previous clearances of the additional predicate devices were leveraged to support the current submission, as recommended in the FDA's Class II Special Controls Guidance document for Resorbable Calcium Salt Bone Void Filler Devices."
This indicates that the clearance was based on demonstrating the new device's material and design equivalence to already cleared devices, rather than new clinical or AI performance studies for this specific submission.
If you have a different document or would like to provide more context about an AI/ML component related to a similar device, please do so, and I would be happy to analyze it.
Ask a specific question about this device
(47 days)
Kuros Biosciences B.V.
MagnetOs Putty is an implant intended to fill bony voids or gaps of the skeletal system, i.e., the extremities, pelvis, intervertebral disc space, and posterolateral spine. These osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. MagnetOs Putty may be used standalone or mixed with autograft. When used in intervertebral body fusion procedures, MagnetOs Putty must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler. MagnetOs Putty resorbs and is replaced with bone during the healing process.
MagnetOs Putty is a synthetic, resorbable, osteoconductive bone void filler for the repair of bony defects. MagnetOs Putty consists of 65-75% Tri-Calcium Phosphate (TCP - Cas(PO4)2) and 25-35% Hydroxyapatite (HA - Ca10(PO4)6 (OH)2) granules with a porous trabecular structure that resembles the interconnected porosity of human cancellous bone. The surface of the granules in MagnetOs Putty is covered with needle-shaped features that are submicron in size. The granules are premixed with a synthetic polymeric binder. The biocompatible polymeric binder is composed of Poly L (Lactic Acid) (PLA) and Poly(Ethylene Glycol) (PEG) in a triblock polymer PLA-PEG-PLA; which consists of 10-20% PLA and 80-90% PEG.
The fast-resorbing polymeric binder in the subject device is designed to improve handling properties, as well as reduce the risk of granules migration. While the polymeric binder is rapidly resorbed after implantation, the granules guide the three-dimensional regeneration of bone in the defect site into which it is implanted.
When placed next to viable host bone, new bone will be deposited on the surface of the implant. The implant resorbs and is replaced by bone during the natural process of bone remodeling.
MagnetOs Putty is a ready-for-use product. Pressure applied by manipulation allows the shaping of the devices to conform to the contours of bony defects. MagnetOs Putty is gamma-sterilized, comes in several sizes in block form and is sterile packaged for single use only.
MagnetOs Putty is MRI (Magnetic Resonance Imaging) Safe.
This document is a 510(k) summary for the MagnetOs Putty, a medical device intended to fill bony voids or gaps. The submission aims to expand its indications for use to include intervertebral disc space in conjunction with an intervertebral body fusion device.
Here's an analysis of the provided text based on your request:
1. Table of Acceptance Criteria and Reported Device Performance:
The document summarizes performance testing but does not explicitly list quantitative acceptance criteria for many of the tests, nor does it provide specific numerical results or performance metrics in a structured table. Instead, it states that the device "met the acceptance criteria" or "passed" certain tests.
Test Type | Acceptance Criteria (as described) | Reported Device Performance (as described) |
---|---|---|
Biocompatibility | In accordance with ISO 10993-1 | Performed and met standards. |
Bacterial Endotoxins Test (BET) | Per Ph.Eur. 2.6.14 and USP . | MagnetOs Putty met the acceptance criteria for the Limulus amebocyte lysate (LAL) test. |
Materials-Mediated Pyrogenicity | Per USP 39-NF34 (Rabbit study). | MagnetOs Putty passed the Materials-Mediated Pyrogenicity Rabbit study and is marketed as "Non-Pyrogenic". |
Sterilization Validation | Per ISO 11137, ensuring a Sterility Assurance Level (SAL) of 10^-6. | Performed and complies with ISO 11137, ensuring a SAL of 10^-6. |
Product and Sterile-Barrier Shelf-Life | Per ISO 11607. | Studies were conducted per ISO 11607. (No specific results given). |
In-vitro study (Bone-like Apatite Layer) | N/A (implied positive outcome for intended mechanism). | Induced the growth of a bone-like apatite layer on the surface of the MagnetOs Granules component following exposure to simulated body fluid. |
2. Sample Size Used for the Test Set and the Data Provenance:
The document refers to "non-clinical testing data, supplemented with clinical data" from a prior clearance (K230736). However, no specific sample sizes for test sets are mentioned for any of the individual tests (biocompatibility, endotoxins, pyrogenicity, sterilization, shelf-life, or in-vitro studies).
- Data Provenance: The document generally refers to "non-clinical testing data" and "animal functional studies," and "in-vitro studies." It also mentions "clinical data" but doesn't specify if this refers to human clinical trials or other types of clinical observations. No explicit mention of country of origin or whether the studies were retrospective or prospective is provided.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts:
This information is not provided in a way that directly answers the question. The document describes various scientific and engineering tests (e.g., LAL test, rabbit study, ISO standards) rather than expert-driven clinical ground truth for a test set. Establishing "ground truth" in this context would typically involve expert interpretation of medical images or patient outcomes, which is not detailed here for a specific test set.
4. Adjudication Method for the Test Set:
This is not applicable or mentioned in the provided text. The performance section describes laboratory and animal studies, not analyses requiring expert adjudication of a test set in the way one would for diagnostic imaging algorithms.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
This is not applicable. The device is a bone void filler, not an AI diagnostic or assistance tool. Therefore, an MRMC study comparing human reader performance with and without AI assistance is not relevant to this device.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done:
This is not applicable. The device is a physical medical implant, not an algorithm.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
For the non-clinical and animal functional studies, the "ground truth" is established by direct observation of biological responses, chemical properties, and physical characteristics based on established scientific protocols and standards (e.g., bone-like apatite layer formation, successful sterilization, absence of pyrogenicity in rabbits).
For the "clinical data" mentioned as supplementary, the specific type of ground truth is not detailed in this summary. It might refer to surgical outcomes, imaging results, or patient follow-up, but the document does not elaborate.
8. The sample size for the training set:
This is not applicable. The MagnetOs Putty is a physical medical device, not an AI/ML algorithm that requires a training set.
9. How the ground truth for the training set was established:
This is not applicable. As it's not an AI/ML algorithm, there is no training set or associated ground truth establishment process.
Ask a specific question about this device
(168 days)
Kuros Biosciences B.V.
MagnetOs Granules is an implant intended to fill bony voids or gaps of the skeletal system, i.e., the extremities, pelvis, intervertebral disc space, and posterolateral spine. These osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure.
When used in posterolateral spine, extremities and pelvis, MagnetOs Granules may be used standalone or mixed with autograft, blood, and/or bone marrow. When used in intervertebral body fusion procedures, MagnetOs Granules must be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler and hydrated with blood. MagnetOs Granules may also be mixed with autograft.
MagnetOs Granules resorbs and is replaced with bone during the healing process.
MagnetOs Granules is a synthetic, resorbable, osteoconductive bone void filler for the repair of bony defects. MagnetOs Granules consists of 65-75% tri-calcium phosphate (TCP - Ca3(PO4)2) and 25-35% hydroxyapatite (HA - Ca10(PO4)6(OH)2) granules with a porous trabecular structure that resembles the interconnected porosity of human cancellous bone. MagnetOs Granules guide the three-dimensional regeneration of bone in the defect site into which it is implanted. New bone will be deposited on the surface of the graft when placed next to viable host bone. The graft resorbs and is replaced by bone during the natural process of bone remodeling. MagnetOs Granules is a ready-to-use product. MagnetOs Granules is provided in vials in a range of product volumes. MagnetOs Granules is gamma-sterilized and sterile packaged for single use only.
The total interconnecting porosity of MagnetOs Granules is 70 ± 15%. Pore diameters in the scaffold range from 0 to 1000 µm (1mm).
The provided document is a 510(k) summary for a medical device called MagnetOs Granules. It does not describe acceptance criteria for a diagnostic AI/ML device, nor does it contain a study that proves a device meets such criteria. Instead, it details the substantial equivalence of MagnetOs Granules to predicate devices for its intended use as a bone void filler.
Therefore, I cannot extract the information required to answer your query. The document mentions "non-clinical testing data," "animal testing," and a "clinical study" for MagnetOs Granules itself, but these are for demonstrating the safety and effectiveness of a bone void filler for orthopedic application, not for evaluating the performance of an AI/ML diagnostic tool against specific acceptance criteria like sensitivity, specificity, or AUC.
The information you've requested (acceptance criteria table, sample size for test set, expert qualifications, adjudication method, MRMC study, standalone performance, ground truth type, training set size, and training set ground truth establishment) are typical for the evaluation of a diagnostic AI/ML algorithm. This document is related to a different type of medical device (a resorbable calcium salt bone void filler) and does not provide these details.
Ask a specific question about this device
(278 days)
Kuros Biosciences B.V.
MagnetOs Putty is an implant intended to fill bony voids or gaps of the skeletal system i.e., the extremities, pelvis and posterolateral spine. MagnetOs Putty may be used standalone or mixed with autograft. These osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. MagnetOs Putty resorbs and is replaced with bone during the healing process.
MagnetOs Putty is a synthetic, resorbable, osteoconductive bone void filler for the repair of bony defects. MagnetOs Putty consists of 65-75% Tri-Calcium Phosphate (TCP - Ca3(PO4)2) and 25-35% Hydroxyapatite (HA - Ca10(PO4)6 (OH)2) granules with a porous trabecular structure that resembles the interconnected porosity of human cancellous bone. The granules are covered with submicron-sized features and are premixed with a synthetic polymeric binder. The biocompatible polymeric binder is composed of Poly L (Lactic Acid) (PLA) and Poly(Ethylene Glycol) (PEG) in a triblock polymer PLA-PEG-PLA; which consists of 10-20% PLA and 80-90% PEG.
The fast-resorbing polymeric binder in the subject device is improve handling properties, as well as reduce the risk of granules migration. While the polymeric binder is rapidly resorbed after implantation, the granules in both devices guide the three-dimensional regeneration of bone in the defect site into which it is implanted.
When placed next to viable host bone, new bone will be deposited on the surface of the implant. The implant resorbs and is replaced by bone during the natural process of bone remodeling. MagnetOs Putty is a ready-for-use product. Pressure applied by manipulation allows the shaping of the devices to conform to the contours of bony defects. MagnetOs Putty is gamma-sterilized, comes in several sizes in block form and is sterile packaged for single use only.
This 510(k) expands the device's indications for use in K181958 as an autograft extender only to also allow use of the device alone in posterolateral spine.
The furnished information primarily discusses the regulatory clearance (510(k)) of MagnetOs Putty and its substantial equivalence to predicate devices, rather than an AI/ML powered device. As such, it does not contain the specific details typically found in studies for AI/ML device performance and acceptance criteria.
Therefore, I cannot provide the requested information regarding acceptance criteria and study details for an AI-powered device, as the provided document pertains to a medical device for bone void filling.
However, I can extract the general acceptance criteria Met by the device for its regulatory clearance as a medical device:
1. Table of Acceptance Criteria and Reported Device Performance:
Acceptance Criteria Category | Reported Device Performance (MagnetOs Putty) |
---|---|
Biocompatibility | Met acceptance criteria (in accordance with ISO 10993-1). |
Endotoxin Testing | Met acceptance criteria for Limulus amebocyte lysate (LAL) test (Ph.Eur. 2.6.14, USP ), and passed Materials-Mediated Pyrogenicity Rabbit study (USP 39-NF34). Marketed as "Non-Pyrogenic". |
Sterilization | Complies with ISO 11137, achieving a Sterility Assurance Level (SAL) of 10⁻⁶. |
Shelf-Life | Product and sterile-barrier shelf-life studies conducted per ISO 11607. |
Performance (Standalone Use in Posterolateral Spine) | Performance was "the same" compared to the primary predicate MagnetOs Granules in a posterolateral spinal fusion (PLF) animal model and confirmed with a small clinical data set. |
Substantial Equivalence | Demonstrated substantial equivalence to predicate devices (MagnetOs Granules K213111, MagnetOs Putty K181958, NuVasive AttraX Putty K191974) in intended use, indications for use, product classification, product code, technological characteristics, materials, and manufacturing process. |
This information does not relate to AI/ML software. Therefore, the following points are not applicable and cannot be answered from the provided text:
- Sample size used for the test set and the data provenance.
- Number of experts used to establish the ground truth for the test set and the qualifications of those experts.
- Adjudication method for the test set.
- If a multi reader multi case (MRMC) comparative effectiveness study was done, and the effect size of how much human readers improve with AI vs without AI assistance.
- If a standalone (i.e. algorithm only without human-in-the-loop performance) was done.
- The type of ground truth used.
- The sample size for the training set.
- How the ground truth for the training set was established.
Ask a specific question about this device
(36 days)
Kuros Biosciences B.V.
MagnetOs Easypack Putty is intended to filly bony voids or gaps of the skeletal system. i.e., the intervertebral disc space, and posterolateral spine. The osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. In the intervertebral disc space and posterolateral spine, MagnetOs Easypack Putty must be used with autograft as a bone extender. When used in intervertebral body fusion procedures, MagnetOs Easypack Putty must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler.
MagnetOs Easypack Putty resorbs and is replaced with bone during the healing process.
MagnetOs Easypack Putty is a synthetic, resorbable, osteoconductive bone void filler for the repair of bony defects, MagnetOs Easypack Putty consists of 65-75% tri-calcium phosphate (TCP - Ca3(PO4)2) and 25-35% hydroxyapatite (HA - Ca10(PO4)6(OH)2) granules, premixed with a synthetic polymeric binder that provides cohesion between the granules.
New bone will be deposited on the surface of the graft when placed next to viable host bone. The graft resorbs and is replaced by bone during the natural process of bone remodeling.
MagnetOs Easypack Putty is a ready-to-use product. Pressure applied by manipulation allows users to shape MagnetOs Easypack Putty to conform to the contours of bony defects. MagnetOs Easypack Putty is provided in open-ended syringes in a range of product volumes. MagnetOs Easypack Putty is gamma-sterilized and sterile packaged for single use only.
The provided document is a 510(k) Summary for a medical device (MagnetOs Easypack Putty) and does not contain detailed information about acceptance criteria or a specific study proving the device meets those criteria in the context of software/AI performance.
This summary primarily focuses on demonstrating substantial equivalence to a predicate device for an expanded indication for use. It mentions general performance testing and supporting rationale, but it does not detail specific acceptance criteria for performance metrics (like sensitivity, specificity, accuracy) or the methodology of an AI/software performance study with a test set, ground truth, or expert involvement as requested in your prompt.
Therefore, I cannot provide the requested information based on the given text. The document describes a physical medical device (bone void filler) and its regulatory clearance process, not a software or AI-driven diagnostic or therapeutic device.
Ask a specific question about this device
(54 days)
Kuros Biosciences B.V.
MagnetOs Flex Matrix is intended to fill bony voids or gaps of the skeletal system, i.e., the intervertebral disc space, and posterolateral spine. The osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. In the intervertebral disc space and posterolateral spine, MagnetOs Flex Matrix must be hydrated with bone marrow aspirate (BMA) and used as an extender to autograft bone. When used in intervertebral body fusion procedures, MagnetOs Flex Matrix must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler.
MagnetOs Flex Matrix resorbs and is replaced with bone during the healing process.
MagnetOs Flex Matrix is a resorbable, osteoconductive bone void filler for the repair of bony defects. The product is biocompatible.
MagnetOs Flex Matrix is a mixture of medical grade collagen and hydroxyapatite and Btricalcium phosphate ceramic (92.5-95.5 wt% MagnetOs Granules and 4.5-7.5 wt% collagen). The ceramic portion of MagnetOs Flex Matrix consists of 75-65% B-Tri-Calcium Phosphate and 25-35% Hydroxyapatite. The collagen is produced of highly purified bioresorbable bovine split skin and consists mainly of collagen type I. The components are mixed in a slurry and lyophilized, which results in a highly porous sponge matrix that provides cohesion between the MagnetOs Granules without inhibiting the granule surface structure.
MagnetOs Flex Matrix is a ready-to-use product. Upon hydration, the material is moldable and allows users to shape MagnetOs Flex Matrix to conform to the contours of bony defects. MagnetOs Flex Matrix is supplied as a ready-to-use strip, it is sterile packaged and gammasterilized for single patient use only.
The provided document is a 510(k) summary for a medical device called MagnetOs Flex Matrix. This type of submission focuses on demonstrating substantial equivalence to a legally marketed predicate device rather than proving objective performance against predefined acceptance criteria for AI/ML devices. Therefore, the document does not contain the information requested in points 1, 2, 3, 4, 5, 6, 7, 8, and 9 about acceptance criteria, specific study details, and training set information typically associated with AI/ML device evaluations.
However, I can extract information related to performance testing that was conducted to support the substantial equivalence claim.
Performance Testing Summary (as described in the document):
The performance testing primarily aimed to demonstrate substantial equivalence to a predicate device, not necessarily to meet specific, quantifiable acceptance criteria in the manner an AI/ML device would.
- Animal Testing: Performed in a rabbit posterolateral fusion model to demonstrate substantial equivalence to a legally marketed predicate device.
- In-vitro Studies: Showed that MagnetOs Flex Matrix induced the growth of a bone-like apatite layer on the surface of the MagnetOs Granules component following exposure to simulated body fluid.
- Other Non-Clinical Testing: In support of a prior clearance (K213959), non-clinical testing data were submitted according to FDA guidance documents. These data covered:
- Physical properties
- Sterilization
- Product shelf life
- Biocompatibility
Missing Information (as per your request):
The document does not provide any of the following information, as it is not a study designed to demonstrate performance against specific acceptance criteria for an AI/ML device:
- A table of acceptance criteria and reported device performance.
- Sample size used for the test set and data provenance.
- Number of experts used to establish ground truth and their qualifications.
- Adjudication method for the test set.
- If a multi-reader, multi-case (MRMC) comparative effectiveness study was done, or effect size of human reader improvement with AI.
- If a standalone (algorithm only) performance was done.
- The type of ground truth used (expert consensus, pathology, outcomes data, etc.).
- The sample size for the training set.
- How the ground truth for the training set was established.
Ask a specific question about this device
(133 days)
Kuros Biosciences B.V.
MagnetOs Easypack Putty is intended to fill bony voids or gaps of the skeletal system, i.e. posterolateral spine. In the posterolateral spine, MagnetOs Easypack Putty must be used with autograft as a bone graft extender. The osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the bony structure.
MagnetOs Easypack Putty resorbs and is replaced with bone during the healing process.
MagnetOs Easypack Putty is a synthetic, resorbable, osteoconductive bone void filler for the repair of bony defects.
MagnetOs Easypack Putty consists of 65–75% tri-calcium phosphate (TCP – Ca3(PO4)2) and 25-35% hydroxyapatite (HA - Ca10(PO4)6(OH)2) granules, premixed with a synthetic polymeric binder that provides cohesion between the granules.
New bone will be deposited on the surface of the graft when placed next to viable host bone. The graft resorbs and is replaced by bone during the natural process of bone remodeling.
MagnetOs Easypack Putty is a ready-to-use product. Pressure applied by manipulation allows users to shape MagnetOs Easypack Putty to conform to the contours of bony defects.
MagnetOs Easypack Putty is provided in open-ended syringes in a range of product volumes. MagnetOs Easypack Putty is gamma-sterilized and sterile packaged for single use only.
This document does not describe a study involving an AI/ML device, therefore, a description of acceptance criteria and the study that proves the device meets the acceptance criteria is not applicable. The provided text is a 510(k) summary for a medical device called "MagnetOs Easypack Putty," which is a resorbable calcium salt bone void filler. It details the device's characteristics, intended use, and demonstrates substantial equivalence to predicate devices through non-clinical testing and animal studies, not AI/ML performance.
Ask a specific question about this device
(136 days)
Kuros Biosciences B.V.
MagnetOs Putty is an implant intended to fill bony voids or gaps of the skeletal system i.e., the extremities, pelvis and posterolateral spine. In the posterolateral spine, MagnetOs Putty must be used with autograft as bone graft extender. In extremities and pelvis, MagnetOs Putty is used alone. These osseous defects may be surgically created of of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. MagnetOs Putty resorbs and is replaced with bone during the healing process.
MagnetOs Putty is a synthetic, resorbable and osteoconductive bone void filler for the repair of bony defects, containing 65-75% beta-Tri-Calcium Phosphate (TCP, Ca3(PO4)2) and 25-35% Hydroxyapatite (HA, Ca5(PO4)3OH) granules, premixed with a synthetic polymeric binder that provides cohesion between the granules.
MagnetOs Putty is gamma-sterilized, comes in several sizes in block form and is sterile packaged for single use only.
This is a premarket notification (510(k)) for a medical device (MagnetOs Putty), not an AI/ML powered device. Therefore, the information requested in terms of acceptance criteria, study details, ground truth, and training data is not directly applicable in the format typically used for AI/ML devices.
However, I can extract and present the relevant information from the provided document regarding the device's performance, testing, and basis for substantial equivalence to its predicate devices, as if this were a non-AI medical device submission.
1. A table of acceptance criteria and the reported device performance
The document does not explicitly state "acceptance criteria" in the quantitative terms typically found for AI/ML device performance. Instead, it demonstrates substantial equivalence based on a comparison to predicate devices, supported by various tests. The reported performance is that the device is "equivalent" to the predicate devices.
Acceptance Criterion (Implied) | Reported Device Performance |
---|---|
Chemical composition equivalent to predicate | Demonstrated equivalent chemical composition |
Physical properties equivalent to predicate | Demonstrated equivalent physical properties |
Biocompatibility in accordance with ISO 10993 series and USP | Assessed using the specified methodologies; no adverse indications or results reported. |
Performance in a posterolateral spine fusion animal model equivalent to predicate | Demonstrated equivalent performance to predicate. |
Performance as a standalone bone void filler in a critical sized femoral animal model equivalent to predicate | Demonstrated equivalent performance to predicate. |
Safety and effectiveness equivalent to predicate devices | Indicated no adverse indications or results; determined to be as safe and effective. |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Animal Studies: The document mentions "a posterolateral spine fusion animal model" and "a critical sized femoral animal model." It does not specify the exact number of animals used in these studies, nor their country of origin. It is implied these were prospective studies as they were conducted to support the 510(k) submission.
- Bench Testing: No "sample size" in the conventional sense is stated for bench tests. These tests are performed on the device material itself.
- Data Provenance: Not explicitly stated for either animal studies or bench testing, but likely associated with the manufacturer (Kuros Biosciences B.V., Netherlands) or testing facilities they contracted.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
This concept of "experts establishing ground truth" is not applicable in this context. The "ground truth" for the device's performance in animal models would be based on histological analysis, imaging, and biomechanical assessments conducted by animal study researchers and pathologists, whose qualifications are not detailed in this summary. For chemical and physical properties, the "ground truth" is derived from established analytical methods.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not applicable. This concept is typically relevant for human reader studies or clinical trials involving subjective human assessment.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This is a medical device (bone void filler), not an AI/ML powered diagnostic or therapeutic aid. No human reader studies or AI assistance are involved.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Not applicable. This device is not an algorithm. Performance of the device itself was evaluated in bench and animal studies (standalone in terms of the device's function as a biological implant).
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
- Biocompatibility: Ground truth is established by adherence to recognized ISO standards (ISO 10993 series) and USP , which define acceptable biological responses.
- Chemical/Physical Properties: Ground truth is established by validated analytical methods (XRD, FTIR, NMR, ICP/MS, SEM, SBF immersion, mercury intrusion porosimetry) and comparison to the known properties of the predicate devices.
- Animal Studies: Ground truth for performance (e.g., bone fusion, defect repair) would be based on pathological assessment (histology, imaging) and potentially functional outcomes in the animal models, as evaluated by veterinary surgeons and pathologists. The document states "demonstrated that the performance of the subject device was equivalent to that of the predicate," implying direct comparative assessment of these outcomes.
8. The sample size for the training set
Not applicable. This device is not an AI/ML algorithm that requires a training set.
9. How the ground truth for the training set was established
Not applicable. See point 8.
Ask a specific question about this device
(86 days)
Kuros Biosciences B.V.
MagnetOs Putty is an implant intended to fill bony voids or gaps of the skeletal system, i.e., posterolateral spine. MagnetOs Putty must be used with autograft as a bone graft extender in the posterolateral spine. These osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. MagnetOs Putty resorbs and is replaced with bone during the healing process.
MagnetOs Putty is a synthetic, resorbable and osteoconductive bone void filler for the repair of bony defects, containing 65-75% Tri-Calcium Phosphate (TCP, Cas(PQ2)>) and 25-35% Hydroxyapatite (HA. Cag(PO2)3OH) granules, premixed with a synthetic polymeric binder that provides cohesion between the granules.
MagnetOs Putty is gamma-sterilized, comes in four sizes in block form and is sterile packaged for single use only.
The provided document is a 510(k) premarket notification for the MagnetOs Putty device. It details the device's substantial equivalence to existing predicate devices, focusing on non-clinical testing. However, it does NOT provide the acceptance criteria or a study that uses such criteria to prove the device meets them in the context of diagnostic accuracy or performance against specific metrics as would be expected for an AI/CADe device.
Therefore, many of the requested sections regarding acceptance criteria, sample sizes, ground truth establishment, expert involvement, and comparative effectiveness studies for AI are not applicable to this document. The document describes a comparison to predicate devices, which is a different type of assessment than proving performance against defined acceptance criteria typically seen for diagnostic devices.
Here's the closest possible interpretation of the requested information based on the provided text:
1. A table of acceptance criteria and the reported device performance
The document does not specify quantitative acceptance criteria in terms of performance metrics (e.g., sensitivity, specificity, accuracy) that the device must achieve. Instead, it demonstrates "substantial equivalence" to predicate devices through various non-clinical tests. The "performance" is implicitly deemed acceptable if it is found to be equivalent to the predicate devices.
Acceptance Criteria (Implied) | Reported Device Performance |
---|---|
Equivalent chemical composition to predicate devices | Achieved through XRD, FTIR, NMR, OVI, ICP/MS analysis |
Equivalent physical properties to predicate devices | Achieved through Mercury intrusion porosimetry, dissolution, IV analysis |
Equivalent surface microstructure and bioactivity to predicate devices | Achieved through SEM and in vitro SBF immersion study |
Biocompatibility in accordance with ISO 10993 standards and USP | Assessed using methodology described in ISO 10993-1, -3, -5, -6, -10, -11 and USP |
Equivalent performance in a posterolateral spine fusion animal model to predicate devices | Demonstrated in a posterolateral spine fusion animal model |
Same intended use as predicate devices | MagnetOs Putty has the same intended use. |
Same product classification and product code (MQV) | MagnetOs Putty has the same classification and product code. |
Similar Indications for Use as predicate devices | MagnetOs Putty has similar Indications for Use. |
Same operating principle as predicate devices | MagnetOs Putty uses the same operating principle. |
Same basic design as predicate devices | MagnetOs Putty incorporates the same basic design. |
Same or very similar materials as predicate devices | MagnetOs Putty incorporates the same or very similar materials. |
Manufactured at the same facility using very similar processes as predicate MagnetOs Granules (K161859) | Manufactured at the same facility using very similar processes. |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
The document mentions an "animal model" for the posterolateral spine fusion study. However, it does not specify the sample size (number of animals or cases) used for this test set, nor does it provide details on data provenance beyond acknowledging it was an "animal model." The studies are pre-clinical, meaning they are conducted in a laboratory setting or on animals, not human patients.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
This information is not provided in the document. Given that the testing included an "animal model" and material characterization, the "ground truth" would likely be established by experimental measurements and observations by laboratory personnel or veterinary specialists, rather than clinical experts like radiologists.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
This information is not provided.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
No such MRMC comparative effectiveness study was described, as this device is a bone void filler, not an AI/diagnostic imaging device that would assist human readers.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
This concept is not applicable to the MagnetOs Putty device, which is a physical implant, not an algorithm.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
For the material characterization, the "ground truth" would be established by scientific measurement techniques (e.g., XRD, FTIR, SEM, ICP/MS, porosimetry) and comparison to known material properties of the predicate devices. For the animal study, the "ground truth" would be established by histological analysis, imaging, or other relevant assessment of bone healing and fusion in the animal model.
8. The sample size for the training set
The concept of a "training set" is not applicable as this is not an AI/machine learning device.
9. How the ground truth for the training set was established
Not applicable.
Ask a specific question about this device
Page 1 of 1